Abstracts tagged "chemokines"

Abstract Number: 1130 • 2016 ACR/ARHP Annual Meeting
Aminopeptidase N/CD13 Induces Monocyte Migration in Vitro and In Vivo and Signals through GPCR, Erk1/2, Jnk, Src, and NFκB
Yuxuan Du¹, W. Alexander Stinson², Phillip Campbell¹, Rachel Morgan¹, Nicholas Lepore¹, Ellen Cealey¹, Jonatan Hervoso¹, Huadong Cui², David Fox³ and M. Asif Amin⁴, ¹Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ⁴Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Aminopeptidase N/CD13 is a metalloproteinase expressed on the surface of fibroblast like synoviocytes (FLS). It is found in soluble form in serum and rheumatoid…
Abstract Number: 1318 • 2016 ACR/ARHP Annual Meeting
Profile of Macrophage-Derived Cytokines and Chemokines of Patients with Chikungunya-Induced Chronic Arthralgia/Arthritis
Idali Martinez¹, Edwin Lopez¹, Zelma L. Rios¹ and Luis M. Vilá², ¹Department of Microbiology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ²Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Chikungunya virus (CHIKV) caused a large epidemic in Puerto Rico in 2014 with more than 30,000 reported cases. Many of the affected individuals developed…
Abstract Number: 1458 • 2016 ACR/ARHP Annual Meeting
Intraadrenal Dendritic Cells Inhibit Corticosterone Response during Collagen-Induced Arthritis – a Role for IL-1β and CXC Chemokines?
Hubert Stangl, Christine Wolff, Martin Lesiak and Rainer Straub, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital Regensburg, Regensburg, Germany
Background/Purpose: In rheumatoid arthritis (RA) and collagen-induced arthritis (CIA) the phenomenon of a relative insufficiency of adrenal glands to produce an adequate amount of anti-inflammatory…
Abstract Number: 2151 • 2016 ACR/ARHP Annual Meeting
Fractalkine (CX3CL1) Is Expressed By Arterial Endothelium and Vascular Smooth Muscle Cells (VSMC) in GCA
Marc Corbera-Bellalta¹, Ester Planas-Rigol², Nekane Terrades-Garcia¹, Marco Antonio Alba¹, Georgina Espígol-Frigolé², Sergio Prieto-González², Jose Hernández-Rodríguez¹ and Maria C. Cid³, ¹Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain
Background/Purpose: The development of giant-cell arteritis (GCA) lesions requires amplification cascades resulting in continuous recruitment of lymphocytes and monocytes. Interferon-gamma (IFNg)- induced or up-regulated chemokines…
Abstract Number: 2153 • 2016 ACR/ARHP Annual Meeting
Syndecans Mediate Rantes/CCL5 Induced MMP-1 and MMP-13 Expression in Rheumatoid Arthritis Synovial Fibroblasts
Solomon Agere, Nahid Akhtar and Salahuddin Ahmed, Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA
Background/Purpose: RANTES/CCL5 (RANTES) is a C-C chemokine that binds to its receptor (CCR5) and initiates inflammatory processes in rheumatoid arthritis (RA) by facilitating leukocyte…
Abstract Number: 2284 • 2016 ACR/ARHP Annual Meeting
Differential Effect of MSU-Crystal Induced Inflammation on Macrophage Polarization
Rashid Ahmed¹, Nicole Yang², Changqi Sun³ and Anthony M. Reginato³, ¹Rhode Island Hospital, The Warren Alpert School of Medicine at Brown University, Providence, RI, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, USA., Boston, MA, ³Division of Rheumatology, Rhode Island Hosital/The Warren Alpert School of Medicine of Brown University, Providence, RI
Background/Purpose: Gouty arthritis is a common inflammatory joint disease that arises in response to the deposition of monosodium urate (MSU) crystals in soft joints, periarticular…
Abstract Number: 2432 • 2016 ACR/ARHP Annual Meeting
Immune Abnormalities Leading to Exaggerated Production of IFN-Gamma (IFNγ) and the Therapeutic Response to an Anti-IFNγ Antibody in a Patient with NRLC4 Mediated Disease
Claudia Bracaglia¹, Giusi Prencipe², Manuela Pardeo¹, Geneviève Lapeyre³, Emiliano Marasco², Antonella Insalaco¹, Walter Ferlin³, Robert Nelson³, Cristina de Min³ and Fabrizio De Benedetti¹, ¹Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ²Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy, ³NovImmune S.A., Geneva, Switzerland
Background/Purpose: Animal and human data suggest that IFNγ plays a pathogenic role in HLH. A phase 2 trial with the anti-IFNγ monoclonal antibody NI-0501 in…
Abstract Number: 13L • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study in Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisanori Umehara³, Toshihiro Nanki⁴, Hideto Akama⁵, Nobuyuki Yasuda⁵, Fumitoshi Tago⁵, Makoto Kawakubo⁵, Seiichiro Hojo⁵, Tetsu Kawano⁶ and Toshio Imai⁶, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Dept. of Internal Medicine, School of Medicine Keio University, Tokyo, Japan, ³Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵EISAI Co. Ltd., Tokyo, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
Abstract Number: 2086 • 2015 ACR/ARHP Annual Meeting
Inhibition of Macrophage Inflammatory Protein 1-Alpha (CCL3) Significantly Reduced Bone Resorption in Vitro and the Development of Erosive Joint Pathology in Collagen-Induced Arthritis
Lauren A. Jordan¹, Ruth Davies¹, Alastair J. D. Robertson², Ann K. Harvey¹, Ernest H. Choy¹, Malin Erlandsson³, Maria I. Bokarewa⁴, Rachel J. Errington¹ and Anwen S. Williams¹, ¹Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ²William Harvey Hospital, Willesborough, Ashford, United Kingdom, ³University of Goteborg, Goteborg, Sweden, ⁴Guldhedsgatan 10, University of Goteborg, Goteborg, Sweden
Background/Purpose: The destruction of bone is a common feature of diseases like rheumatoid arthritis (RA) and multiple myeloma (MM). CCL3 is significantly elevated in the…
Abstract Number: 2834 • 2015 ACR/ARHP Annual Meeting
CXCL10 Expression Is Elevated in Synovial Fluid of Psoriatic Arthritis Patients
Anastasiya Muntyanu¹, Fatima Abji², Kun Liang³, Vinod Chandran⁴ and Dafna Gladman⁴, ¹Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA), an inflammatory musculoskeletal disease, develops in approximately 30% of patients with psoriasis. We previously identified C-X-C motif chemokine 10 (CXCL10) as…
Abstract Number: 2993 • 2015 ACR/ARHP Annual Meeting
Serum CXCL4 Increase in Patients with Undifferentiated Connective Tissue Disease at Risk for Systemic Sclerosis Is Associated with Anti-Scl70 Antibodies and ICAM-1, a Marker of Endothelial Activation
Serena Vettori¹, Rosaria Irace², Veronica Giacco², Antonella Riccardi², Lucia Vicedomini², Luciana Pellecchia² and Gabriele Valentini², ¹Department of Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ²Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy
Background/Purpose: CXCL4 is a pleiotropic antiangiogenic and immunomodulatory chemokine, that has been shown to be increased in the sera of patients with systemic sclerosis (SSc)…
Abstract Number: 87 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Risk Gene CCR6 Polymorphism: Drug-Induced “Reversal” of ER Binding and the Expression of Inflammatory Mediators -Potential Molecular Mechanism Links Between Estrogen and RA
Ming-Fen Ho¹, Richard M. Weinshilboum², Liewei Wang², James N. Ingle³ and Tim Bongartz⁴, ¹Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Rochester, Rochester, MN, ²Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, ³Department of Medical Oncology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: The rheumatoid arthritis (RA) risk locus CCR6 SNP rs3093024, is in tight linkage disequilibrium with rs3093023 which has been associated with RA risk. RA…
Abstract Number: 905 • 2015 ACR/ARHP Annual Meeting
Citrullinated Epithelial-Derived Neutrophil-Activating Peptide 78 (ENA-78/CXCL5) Induces Monocyte Migration Via JNK and NFκB Signaling Pathways
Ray A. Ohara¹, Nicholas Lepore², W. Alexander Stinson³, Gautam Edhayan³, Phillip L. Campbell¹, Sarah Arwani¹, Rachel Morgan¹, Jeffrey H. Ruth¹, Alisa E. Koch^1,4, David A. Fox¹ and M. Asif Amin¹, ¹Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²University of Michigan, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by monocyte (MN) infiltration into the synovium. Citrullination is a post-translational modification of arginine to…
Abstract Number: 1139 • 2015 ACR/ARHP Annual Meeting
Differential Inflammatory Profile in Experimental Models of Arthritis
Ana C. Ortiz¹, Anne Crilly¹, Lynette Dunning¹, Carmen Huesa¹, C. S. Goodyear², John C. Lockhart¹, William R. Ferrell² and Iain B. McInnes², ¹Institute of Biomedical and Environmental Health Research, University of the West of Scotland, Paisley, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: While osteoarthritis (OA) in humans is characterized by cartilage degradation, osteophyte formation and joint remodeling, inflammation and synovitis are now recognized to contribute to…
Abstract Number: 1148 • 2015 ACR/ARHP Annual Meeting
The Role of TRPC6 in CXCR2-Mediated Chondrocyte Phenotypic Stability
Joanna Sherwood¹, Jessica Bertrand¹, Francesco Dell'Accio² and Thomas Pap³, ¹Institute for Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany, ²EMR, Queen Mary's School of Medicine and Dentistry, London, United Kingdom, ³Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany
Background/Purpose: We have recently demonstrated that ELR+ CXC chemokines signaling via the CXCR2 receptor, are produced by healthy chondrocytes and are retained within the cartilage…

« Previous Page
1
…
5
6
7
8
9
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.